Compare POET & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | POET | AQST |
|---|---|---|
| Founded | 1972 | 2004 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 834.1M | 707.6M |
| IPO Year | N/A | 2018 |
| Metric | POET | AQST |
|---|---|---|
| Price | $7.18 | $6.17 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $8.83 |
| AVG Volume (30 Days) | ★ 7.1M | 2.3M |
| Earning Date | 11-13-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $762,695.00 | ★ $43,397,000.00 |
| Revenue This Year | $2,939.08 | N/A |
| Revenue Next Year | $710.17 | $52.34 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 535.87 | N/A |
| 52 Week Low | $3.09 | $2.12 |
| 52 Week High | $9.41 | $7.55 |
| Indicator | POET | AQST |
|---|---|---|
| Relative Strength Index (RSI) | 57.53 | 50.89 |
| Support Level | $6.19 | $5.86 |
| Resistance Level | $7.75 | $6.59 |
| Average True Range (ATR) | 0.55 | 0.29 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 59.17 | 52.84 |
POET Technologies Inc is a design and development company offering high-speed optical engines, light source products, and custom optical modules to the artificial intelligence systems market and hyperscale data centers. Its integration solutions are based on the POET Optical Interposer, a novel, patented platform that allows the seamless integration of electronic and photonic devices into a single chip using wafer-level semiconductor manufacturing techniques. POET's Optical Interposer platform also solves device integration challenges across a broad range of communication, computing, and sensing applications. The company operates geographically in the United States, Canada, Singapore and China.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.